Effectiveness of a Digital Therapeutic on Type 2 Diabetes
Primary Purpose
Type2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
FareWell Program
Sponsored by

About this trial
This is an interventional treatment trial for Type2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- diagnosis of type 2 diabetes
Exclusion Criteria:
- Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.
- Does not have a smartphone (either an iPhone or Android phone)
Sites / Locations
- FareWell LLC
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
FareWell Program
Arm Description
All participants receive the FareWell Program intervention in this evaluation study
Outcomes
Primary Outcome Measures
Level of engagement with the assigned mobile app
How do participants interact with the digital program (e.g. feature use, coaching calls completed, targets tracked, targets met)
Secondary Outcome Measures
Change in self-reported Hemoglobin A1c
Comparison of baseline and end program self reported Hemoglobin A1c
Change in self-reported diabetes medication type or dose
Comparison of diabetes medications reported at baseline to any changes reported at the end of the study or mid-study
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03369626
Brief Title
Effectiveness of a Digital Therapeutic on Type 2 Diabetes
Official Title
Effectiveness of a Digital Therapeutic in a Geographically Distributed Population With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
July 26, 2017 (Actual)
Primary Completion Date
January 31, 2018 (Actual)
Study Completion Date
February 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
FareWell
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the "Program") aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. The current study is designed to evaluate to what degree adults with Type 2 Diabetes engaged with the Program can improve glycemic control and/or decrease medication needs.
Detailed Description
The Program aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. It includes meal planning tools, smart shopping lists, recipes curated by a physician, dietitian and chef educator, daily self-monitoring features with personalized weekly goals, bi-weekly live one-on-one health coaching and support from an online member community, and an educational curriculum. Subjects in the Program may receive support from other members of a Care Team (lifestyle medicine physician, chef educator, registered dietitian and/or psychologist/psychiatrist) as needed. The Care Team does not provide medical advice, nor replace traditional medical care. Instead, the Care Team encourages behavior change by providing support and sharing its expertise.
Study participants will have access to the Program for a twelve week period and will be asked to complete short health surveys at baseline and at the end of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
evaluation of pre/post measures of a single group
Masking
None (Open Label)
Allocation
N/A
Enrollment
118 (Actual)
8. Arms, Groups, and Interventions
Arm Title
FareWell Program
Arm Type
Other
Arm Description
All participants receive the FareWell Program intervention in this evaluation study
Intervention Type
Behavioral
Intervention Name(s)
FareWell Program
Intervention Description
The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
Primary Outcome Measure Information:
Title
Level of engagement with the assigned mobile app
Description
How do participants interact with the digital program (e.g. feature use, coaching calls completed, targets tracked, targets met)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in self-reported Hemoglobin A1c
Description
Comparison of baseline and end program self reported Hemoglobin A1c
Time Frame
12 weeks
Title
Change in self-reported diabetes medication type or dose
Description
Comparison of diabetes medications reported at baseline to any changes reported at the end of the study or mid-study
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of type 2 diabetes
Exclusion Criteria:
Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.
Does not have a smartphone (either an iPhone or Android phone)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Berman, MD
Organizational Affiliation
FareWell
Official's Role
Principal Investigator
Facility Information:
Facility Name
FareWell LLC
City
San Francisco
State/Province
California
ZIP/Postal Code
94108
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Effectiveness of a Digital Therapeutic on Type 2 Diabetes
We'll reach out to this number within 24 hrs